Abstract
In a Perspective, Klaus Pantel discusses prospects for use of cell-free DNA and circulating tumor cells in cancer detection.
Highlights
Analysis of circulating cell-free DNA or circulating tumor cells (CTCs), known as liquid biopsy, has received substantial attention in recent years owing to the potential benefits for detecting tumors and informing treatment [1]. cfDNA is released into the blood by apoptotic and necrotic cells, and cancer patients have increased concentrations of cfDNA [2]
The choice of cfDNA sequencing technology depends on the fraction of circulating tumor-derived DNA within the pool of cfDNA, which is usually much higher (>5%–10%) in patients with advanced disease compared to patients at earlier disease stages (
Focusing on population groups at an elevated risk of developing cancer (e.g., chronic obstructive pulmonary disease (COPD) patients or patients with a well-known genetic predisposition to breast or colon cancer) is a good strategy to speed up the process of testing and validation of new approaches and technologies
Summary
OPEN ACCESS Citation: Pantel K (2016) Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection. 115749, resources of which are composed of financial contribution from the European Union’s Seventh Framework Program (FP7/2007-2013) and EFPIA companies’ in-kind contribution.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
